Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (January 2018)
38 slides from Windtree Therapeutics's investor presentation, Jan 8, 2018
Slide 1: Corporate Presentation January 2018
Sv we WINDTREE Corporate Presentation January 2018 OTCQB:WINTD
Slide 2: Forward-looking Statement
Forward-looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreem
Slide 3: Windtree Therapeutics
Windtree Therapeutics = Public, small cap biopharmaceutical / medical device company = Based in Warrington, PA with approximately 27 employees = Focused in the acute respiratory area with a lead program expected to address a significant need and expand the Respiratory Distress Syndrome (RDS) in prem
Slide 4: Respiratory Distress Syndrome (RDS)
Respiratory Distress Syndrome (RDS) Primary characteristic is surfactant deficiency in underdeveloped lungs of premature infants (born with a lack of natural lung surfactant required for open airways and proper gas exchange — O, in and CO, out) American Academy of Pediatrics guidelines recommend pro
Slide 5: Current RDS Treatment Pathways
Current RDS Treatment Pathways Initial treatment options include _— * invasive and non-invasive methods: Surfactant Invasive mechanical NCPAP Support until presumptive Therapy + ventilation (IMV) endogenous surfactant production f fy a * Animal-derived surfactant * Requires sustained * Non-invasive
Slide 6: Clinicians Seeking a NonInvasive Way to Deliver Surfactant
Clinicians Seeking a NonInvasive Way to Deliver Surfactant What is wanted: Y¥ Avoid the risks and complications associated with delivery of surfactant therapy via intubation and mechanical ventilation Y Possibility of repeat doses Y Avoid clinical instability associated with administration of liquid
Slide 7: Windtree Technology Platform - AEROSURF
Windtree Technology Platform - AEROSURF® Potential to Provide Both Non-Invasive and Invasive Solutions to Treat RDS Proprietary Synthetic KL4 Surfactant Designed to be structurally similar to human lung surfactant Liquid KLa surfactant (intratracheal instillate) for RDS approved by the FDA Lyophiliz
Slide 8: Transformative Potential of AEROSURF
Transformative Potential of AEROSURF® RISKS Surfactant Therapy Reysrsing surfactant deficientyhas ‘a profound positive impact on respiration Surfactant therapy delivers near-immediate clinical improvement BPD Infection, ventilator-induced pneumonia Pain, discomfor Lofig-term impacts including\vocal
Slide 9: Potential Drivers of AEROSURF Opportunity
Potential Drivers of AEROSURF® Opportunity #1 20-30% fPrice Market stated unmet reduction in (but § Total Expansion needinRDS —nCPAP failure is Hospital Cost) P meaningful “Noninvasive Results in >40% Potential for Potential to bring surfactant delivery” reported, positive health surfactant therapy
Slide 10: Significant RDS Global Revenue Opportunity
Significant RDS Global Revenue Opportunity 8 to 10 Million Low Birth Weight Children Born Every Year Globally Estimated 2016 Annual Revenue * Only 50% to 60% of RDS patients currently treated with surfactant therapy Invasive surfactant therapy only’ us $90 million * Opportunity to expand $800MM - tr
Slide 11: Medical Device and Device Studies
Medical Device and Device Studies
Slide 12: Innovative Aerosol Delivery System (ADS)
tary Innovative Aerosol Delivery System (ADS) Designed specifically to aerosolize and deliver KLa surfactant * AEROSURF® innovation made possible by novel medical device * Unique aerosol delivery system (ADS) technology utilizing pressure and heated capillary has demonstrated ability to break throug
Slide 13: ADS Technology Provides Better Output Rate
ADS Technology Provides Better Output Rate Aerosolizes surfactant as well as saline Aerosol output rate Output with Saline (mL/minute) Output with KL, Surfactant (30mg TPL/mL) 120 220 12 2 ¥ 08 a i > & z 0.4 =e 2 a Ae g ea * Ooo sé pee oe; oe, £ « Saline output of ADS technology is close to KL, surf
Slide 14: Lung Deposition Study in Non-Human Primates
WO eezeeunics Lung Deposition Study in Non-Human Primates * Use of non-human primates (cynomolgus macaques) - Nose, throat, & lung anatomy comparable to infants; respiratory function similar to preterm infants * Radiolabeled KL4 surfactant aerosolized using Aerosol Delivery System (ADS), delivered v
Slide 15: AEROSURF Clinical Studies
AEROSURF” Clinical Studies GS winvtREE Py
Slide 16: AEROSURF Phase Program Components
ER AEROSURF” Phase 2 Program Components Study / Activity Rationale / Objective pst | Phase 2a 2a Expansion Phase 2a Phase 2b Other Studies: Observational Study Lung Deposition Study Other Activities: Licensing in Asia Device Development FDA Interaction Initial safety & tolerability (29-34 wk gestati
Slide 17: nCPAP Failure Through Hours by Dose Group
45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours Time to nCPAP Failure Time Until any Intubation - Dosing Group 3&4 ata: 0106/2016 100% oof eal ~' L 80% + 60% 21/40 40%, ‘Subjects Not Intubated (%) Percent Subjects Failed 20% r T T 0% ° 2 ™ 6 © CPAP Only 75 & 100 mey/| (45.860 min) ‘Tre
Slide 18: AEROSURF Safety and Tolerability Assessment
AEROSURF® Safety and Tolerability Assessment = The FDA requested that we conduct a separate safety study in smaller premature infants before including them in blinded studies Multicenter, randomized, open-label, controlled study in 48 premature infants 26 to 28 weeks GA receiving nCPAP for RDS to ev
Slide 19: Observation Related to Bronchopulmonary Dysplasia (BPD)
AEROSURF® Potentially Important Observation Related to Bronchopulmonary Dysplasia (BPD) BPD Rate Patients AEROSURF 0% 0/24 Control 25% 6/24 Bronchopulmonary Dysplasia (BPD) or chronic lung disease of the newborn is one of the most common complications of prematurity and RDS treatments. It occurs in
Slide 20: AEROSURF Phase 2b Study
AEROSURF” Phase 2b Study (28 to 32 wk GA) Trial Objectives Trial Design 221 Patients Enrolled * Evaluate safety and * 3 dose groups: ili North tolerability 25 minute, 40mg/kg pen (up to 2 repeat doses) 34% * Demonstrate efficacy ¥50 minute, 80m¢/kg * Determine effect size (up to 2 repeat doses) for
Slide 21: AEROSURF Phase 2b Incidence of nCPAP Failure
AEROSURF® Phase 2b Incidence of nCPAP Failure Preplanned mITT Without Treatment Interruptions Demonstrates Targeted Reduction * All Sites 45% aa 4 27% 40% relative reduction 35% + 32% 30% 25% 20% CPAP Only 40 mg/kg 80 mg/kg (N=71) (25 min) (50 min) (N=64) (N=44) 60% 50% +} 40% 30% 20% + 10% + 0% | U
Slide 22: Potential for Reduced Respiratory Support
AEROSURF® - Potential for Reduced Respiratory Support in Patients Who Failed nCPAP When on AEROSURF 140 120 100 20 60 40 20 ° 80me/ke, AcPAP Only 8Ome/ke ‘CPAP Only (n=27) (n=23) (n=29) (n=26) Hours Mechanical Ventilation Supplemental Oxygen, In patients who failed nCPAP and required intubation and
Slide 23: Safety & Tolerability Profile
- Safety & Tolerability Profile Similar for Treatment and Control Populations = The adverse event and serious adverse event profile was similar across the 3 groups = Complications of prematurity were also similar 40 mg/kg 80 mg/kg | nCPAP Only (25 min) (50 min) Acquired Sepsis 12 ( 18%) 13 ( 20%) 16
Slide 24: Summary of Efficacy Signals in the Phase 2 Program
Summary of Efficacy Signals in the Phase 2 Program Post-hoc pooled analysis of Phase 2 failure rates. 28% = Post-hoc pooled analysis of patients inthe —s« mud relative phase 2 program (3 studies) treated in 40% 36% ee doses > 45 minutes dosed as intended 30% (uninterrupted) shows a notable reduction
Slide 25: Evolution of Aerosolized Delivery System from Phase 2 to Phase 3
Si @ Evolution of Aerosolized Delivery System (ADS) from Phase 2 to the Next Generation, Phase 3 / “Go to Market” Device Phase 2 Phase 3 / Commercial icons — palaces eae o. sve sor ater omer pon Le acu merge ty “2012 ~ 2017 + 2018 and beyond * Developed in conjunction with Battelle s Daveloping ineo
Slide 26: Complete Device Development and Transition to Next Generation ADS
Complete Device Development and Transition to Next Generation ADS in 2Q 2018 Next Generation ADS Features Addressing Filter Clogging = Designed to utilize the same aerosol = Filter diameter doubled delivery technology to match © Surface cross section| important aerosol characteristics of increased b
Slide 27: AEROSURF Clinical Development Next Steps for 2018
AEROSURF® Clinical Development Next Steps for 2018 Generate the strongest possible position and transition to phase 3 Execute a Bridge Study to transition the new, Next Gen device in order to meet the following objectives: 1. Demonstrate adequate, consistent performance for the new Next Gen device —
Slide 28: AEROSURF Bridge Study
AEROSURF® Bridge Study Blinded study; nCPAP alone as Dose: 50 min. with up to 4 repeat doses; control versus adding minimum 20 minute wait between doses AEROSURF® treatment * Ph2b was 50 min. high dose, 2 repeats possible with a 2 hour wait between = GA range: 26-32 weeks doses * N=70 planned (35 pe
Slide 29: Program Evolution and Changes Intended to Increase Probability of Success
Program Evolution and Changes Intended to Increase the Probability of Technical Success and Continue to Strengthened Data = We have reproduced positive results in our Phase 2a and Phase 2b and have learning’s to apply in trial design and execution = Utilize the Next Gen ADS which is designed to miti
Slide 30: Other Potential Development Activities
Other Potential Development Activities - Lyophilized Lucinactant (LS) - Preclinical Activities GS winvtREE
Slide 31: Lyophilized Lucinactant
Lyophilized Lucinactant A Second Asset Can Expand the Opportunity Lyophilized Lucinactant LS Characteristics Lyophilized dosage form of our KL4 surfactant drug product that was previously approved by the FDA asa liquid dosage form Currently used in AEROSURF® development program Improvements and bene
Slide 32: Leverage Technology to Advance Acute Pulmonary Disease Care Beyond RDS
Leverage our Innovative Technology to Advance Acute Pulmonary Disease Care and Outcomes Beyond RDS as = Program Focus HPhase2 Potential Application ALI - Radiation Preclinical (7 studies) Prevention of acute & AG anes Lung chronic changes (fibrotic) EEO Nee aE Ey; a Mitigate lung injury, ‘SARS, H1N1
Slide 33: Platform Exclusivities
Platform Exclusivities Broad Multi-Faceted Exclusivity Portfolio Regulatory Exclusivities * Orphan Drug Designation in RDS for the U.S. and EU FDA Patents = Lyophilized KL4 Surfactant Portfolio - to 2033 eae = Aerosol Delivery System Portfolio - through 2031+ Trade Secrets/Know-How = Methods of Manu
Slide 34: 2017 Accomplishments
17 - A Productiv 2a Study in 26-28 wk GA Regulatory GS winvtREE BO tree 2017 Accomplishments
Slide 35: 2018 Objectives
2018 Objectives Complete Device Development delivering an extremely consistent, high performing Phase 3 / “go to market” drug delivery platform C=) Solid execution in the clinic with the FDA ro Bridge Study AEROSURF and Lyo Lucinactant LS Global Regulatory Clarity and employed in development 2 Succe
Slide 36: AEROSURF Development and Deliverables Overview
AEROSURF® Development and Deliverables Overview 2018 a @ | @ I e i a Le] oun: Staines J Device Clinical Clinical Start Up Activities EU=Scientific Advice \ EU--Ped. Investigation Plan (PIP) j Regulatory . A, J FDA= Ped. study Plan (PSP) FDA=L5 Advice Medical Devi Review 112018 2.2018 / Mid-2019 v Ne
Slide 37: Value Creating Potential
se B Value Creating Potential ) 56 WINDTREE THERAPEUTICS™ = Potentially transformative therapy addressing both the unmet efficacy and safety needs in the important, acute neonatology market = Multiple phase 2 clinical trials producing and replicating efficacy while continuing to build safety and tol
Slide 38: Windtree Therapeutics
Windtree Therap “Striving to deliver Hope for a Lifetime!” GS winvtREE ue
Windtree Therapeutics — Investor Presentation (January 2018) on 6ix